TELA Bio Reports First Quarter 2024 Financial Results

Rhea-AI Summary

TELA Bio, Inc. reported strong financial results for Q1 2024, with revenue reaching $16.6 million, a 39% increase from the same period in 2023. The company achieved its 13th consecutive quarter of over 35% year-over-year growth and increased full-year revenue guidance to $74.5 million to $76.5 million. Gross profit was $11.3 million, operating expenses rose to $23.7 million, resulting in a loss from operations of $4.8 million. However, a one-time gain of $7.6 million from the sale of assets to MiMedx helped offset the loss, leading to a net loss of $5.7 million.

Positive

• TELA Bio reported strong revenue growth of 39% in Q1 2024, achieving its 13th consecutive quarter of over 35% year-over-year growth.

• The company increased its full-year revenue guidance to $74.5 million to $76.5 million, representing 27% to 31% year-over-year growth.

• Gross profit reached $11.3 million, indicating a strong gross margin of 68% of revenue due to improvements in inventory management.

Negative

• Operating expenses increased to $23.7 million in Q1 2024, primarily driven by higher compensation costs and employee-related expenses from additional headcount, leading to a loss from operations of $4.8 million.

• The net loss in Q1 2024 was $5.7 million, despite a one-time gain of $7.6 million from the sale of assets to MiMedx, indicating ongoing challenges in achieving profitability.

Insights

Financial Analyst

TELA Bio's revenue growth, marked at 39% over the prior year, indicates a robust increase in product demand, especially for their OviTex® product lines, which is a positive sign of market reception. The consistency of this growth pattern, being the 13th consecutive quarter of at least 35% year-over-year growth, suggests a strong sales strategy and effective market penetration. This could be indicative of the company's ability to sustain growth in the foreseeable future.

The gross profit margin improvement to 68% from 66% demonstrates an increased efficiency in inventory management. However, investors should note the significant increase in operating expenses, driven by expansion and R&D efforts, which are essential for long-term growth but currently contribute to operational losses. It's noteworthy that losses from operations have decreased due to a one-time gain from the sale of NIVIS assets, which may not be indicative of regular business operations.

Furthermore, the revision of full-year revenue guidance upwards to a range of $74.5 million to $76.5 million suggests management's confidence in continued growth and may signal to investors an optimistic outlook for the company's financial performance. However, such guidance should be considered in light of the current market conditions and competitive landscape.

Market Research Analyst

The entry into the robotic-assisted surgical space with the launch of Robotic-Compatible OviTex IHR underscores TELA Bio's strategy to adapt to evolving surgical techniques and market demands. Integration into laparoscopic and robotic-assisted surgeries could widen the addressable market and potentially increase market share. This move aligns with industry trends toward minimally invasive surgeries, which are gaining preference due to reduced recovery times and complications.

An emphasis on the balance of the sales force between Hernia and PRS franchises indicates a diversification strategy that may help mitigate risks associated with reliance on a single product line. By focusing on both segments, TELA Bio could leverage cross-selling opportunities and increase customer retention. The appointment of a VP of Medical Affairs and Surgeon Strategy may contribute to stronger clinical credibility and relationships with key opinion leaders in the medical community, further aiding sales efforts.

Medical Research Analyst

The pronounced revenue increase in OviTex PRS Reinforced Tissue Matrix products, by approximately 54%, is reflective of their deepening footprint in the surgical reconstruction market. Their offerings in this domain are resonating with the needs of surgeons and patients, suggesting both clinical acceptance and effectiveness. This product uptake can be read as an indicator of the company's robust R&D capabilities and its alignment with market needs for innovative soft-tissue reconstruction solutions.

The strategic appointment of Dr. Howard N. Langstein as Vice President of Medical Affairs and Surgeon Strategy indicates an investment in the medical expertise and leadership required to navigate the complex regulatory and clinical landscape. This move may help TELA Bio to further refine its strategies for product development and commercialization, ensuring that their offerings meet both surgeon expectations and patient outcomes.

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.

Recent Highlights

• Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;
• Delivered the 13th consecutive quarter of at least 35% year-over-year growth;
• Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in a year-over-year revenue increase for each product of approximately 31% and 54%, respectively;
• Appointed Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy;
• Commenced full U.S. commercial launch of Robotic-Compatible OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically for use in laparoscopic and robotic-assisted inguinal hernia repairs; and
• Increased full year 2024 revenue guidance to $74.5 million to $76.5 million, representing 27% to 31% year-over-year growth.

“We’ve begun 2024 with strong momentum led by a maturing sales force, strategic product portfolio launches, and sustained market share growth across our OviTex portfolio,” said Antony Koblish, co-founder, President, and Chief Executive Officer of TELA Bio. “TELA Bio is focused on optimizing this growth phase, driving our sales force towards a more balanced selling approach across the Hernia and PRS franchises, generating increasing operating leverage over time, and continuing to deliver value to surgeons and patients. Q1 was a strong quarter and we believe the rest of 2024 will continue to showcase the progress TELA is delivering on key strategic priorities.”

First Quarter 2024 Financial Results

Revenue was $16.6 million in the first quarter of 2024, an increase of 39% compared to the same period in 2023. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales.

Gross profit was $11.3 million in the first quarter of 2024, or 68% of revenue, compared to $7.9 million, or 66% of revenue, in the same period in 2023. The increase in gross margin was primarily due to a lower charge for excess and obsolete inventory as a percentage of revenue due to improvements in inventory management.

Operating expenses were $23.7 million in the first quarter of 2024, compared to $19.2 million in the same period in 2023. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, consulting, and higher costs for research and development activities.

Loss from operations was $4.8 million in the first quarter of 2024, compared to a loss from operations of $11.3 million in the same period in 2023. The decrease was driven primarily by the recognition of a one-time gain of $7.6 million from the sale of certain assets related to the NIVIS Fibrillar Collagen Pack Device (“NIVIS”) to MiMedx in March 2024, subject to adjustment in future periods as we reassess our estimate of variable consideration from the transaction.

Net loss was $5.7 million in the first quarter of 2024, compared to a net loss of $12.0 million in the same period in 2023.

Conference Call

TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 9, 2024 to discuss its first quarter 2024 financial results. Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the Events & Presentations page of the investor section of TELA's website.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. Such forward-looking statements include statements relating to our expected revenue and revenue growth for the full year 2024. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic conditions, including any lingering effects of the COVID-19 pandemic and other public health crises, recessionary concerns, banking instability, increasing market interest rates, and inflationary pressures, potentially impacting our ability to market our products, demand for our products due to the deferral of elective procedures, the labor and staffing environment in the healthcare industry, disruption in our supply chain, or pricing pressures concerning our products or the procedures using our products; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance our product offerings; development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; product defects or failures; and total estimated consideration related to the NIVIS transaction. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact
Louisa Smith
ir@telabio.com

TELA Bio, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited)
	March 31,				December 31,
	2024				2023
Assets
Current assets:
Cash and cash equivalents	$	37,143			$	46,729
Accounts receivable, net of allowances of $303 and $416		9,955				9,737
Inventory		13,602				13,162
Prepaid expenses and other assets		1,918				2,098
Total current assets		62,618				71,726
Property and equipment, net		2,325				1,984
Intangible assets, net		2,024				2,119
Right-of-use assets		1,904				1,954
Other long-term assets		2,701				—
Restricted cash		265				265
Total assets	$	71,837			$	78,048
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	3,357			$	1,667
Accrued expenses and other current liabilities		11,822				15,300
Total current liabilities		15,179				16,967
Long-term debt		40,665				40,515
Other long-term liabilities		1,609				1,685
Total liabilities		57,453				59,167
Stockholders’ equity:
Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding		—				—
Common stock; $0.001 par value: 200,000,000 shares authorized; 24,653,939 and 24,494,675 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively		25				24
Additional paid-in capital		340,812				339,655
Accumulated other comprehensive income		97				91
Accumulated deficit		(326,550	)			(320,889	)
Total stockholders’ equity		14,384				18,881
Total liabilities and stockholders’ equity	$	71,837			$	78,048

TELA Bio, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)
	Three months ended March 31,
	2024				2023
Revenue	$	16,603			$	11,909
Cost of revenue (excluding amortization of intangible assets)		5,172				3,916
Amortization of intangible assets		95				95
Gross profit		11,336				7,898
Operating expenses:
Sales and marketing		17,520				13,466
General and administrative		3,829				3,634
Research and development		2,393				2,052
Total operating expenses		23,742				19,152
Other operating income:
Gain on sale of product line		(7,580	)			—
Loss from operations		(4,826	)			(11,254	)
Other expense:
Interest expense		(1,332	)			(1,246	)
Other income		497				473
Total other expense		(835	)			(773	)
Net loss	$	(5,661	)		$	(12,027	)
Net loss per common share, basic and diluted	$	(0.23	)		$	(0.63	)
Weighted average common shares outstanding, basic and diluted		24,579,386				19,185,621
Comprehensive loss:
Net loss	$	(5,661	)		$	(12,027	)
Foreign currency translation adjustment		6				(30	)
Comprehensive loss	$	(5,655	)		$	(12,057	)

FAQ

What was TELA Bio's revenue for the first quarter of 2024?

TELA Bio reported revenue of $16.6 million for the first quarter of 2024.

How much did TELA Bio's revenue grow in Q1 2024 compared to the same period in 2023?

TELA Bio's revenue in Q1 2024 increased by 39% compared to the same period in 2023.

Who was appointed as Vice President of Medical Affairs and Surgeon Strategy at TELA Bio?

Howard N. Langstein, MD, FACS, was appointed as Vice President of Medical Affairs and Surgeon Strategy at TELA Bio.

What was TELA Bio's gross profit in the first quarter of 2024?

TELA Bio's gross profit in the first quarter of 2024 was $11.3 million.

What was TELA Bio's net loss in Q1 2024?

TELA Bio's net loss in Q1 2024 was $5.7 million.